Eli Lilly and Company (LLY)vsPuma Biotechnology Inc (PBYI)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
PBYI
Puma Biotechnology Inc
$7.48
-0.80%
HEALTHCARE · Cap: $382.08M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 28441% more annual revenue ($65.18B vs $228.37M). LLY leads profitability with a 31.7% profit margin vs 13.6%. PBYI appears more attractively valued with a PEG of 0.03. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
PBYI
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+76.6%
Fair Value
$28.43
Current Price
$7.48
$20.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Growing faster than its price suggests
Every $100 of equity generates 28 in profit
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 22.7%
Revenue surging 27.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
Smaller company, higher risk/reward
Earnings declined 34.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : PBYI
The strongest argument for PBYI centers on PEG Ratio, Return on Equity, P/E Ratio. Revenue growth of 27.7% demonstrates continued momentum. PEG of 0.03 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : PBYI
The primary concerns for PBYI are Market Cap, EPS Growth.
Key Dynamics to Monitor
PBYI carries more volatility with a beta of 1.18 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 71/100), backed by strong 31.7% margins and 42.6% revenue growth. PBYI offers better value entry with a 76.6% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Puma Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?